APE1/Ref-1 is an essential DNA repair/gene regulatory protein in mammals of which intracellular level significantly affects cellular sensitivity to genotoxicants. The apurinic/apyrimidinic endonuclease 1 (APE1) functions are altered by phosphorylation and acetylation. We here report that APE1 is also modified by ubiquitination. APE1 ubiquitination occurred specifically at Lys residues near the N-terminus, and was markedly enhanced by mouse double minute 2 (MDM2), the major intracellular p53 inhibitor. Moreover, DNA-damaging reagents and nutlin-3, an inhibitor of MDM2-p53 interaction, increased APE1 ubiquitination in the presence of p53. Downmodulation of MDM2 increased APE1 level, suggesting that MDM2-mediated ubiquitination can be a signal for APE1 degradation. In addition, unlike the wild-type APE1, ubiquitin-APE1 fusion proteins were predominantly present in the cytoplasm. Therefore, monoubiquitination not only is a prerequisite for degradation, but may also alter the APE1 activities in cells. These results reveal a novel regulation of APE1 through ubiquitination.
Introduction
Oxidative DNA damage is continuously generated in cells and is mutagenic and cytotoxic (Fishel and Kelley, 2007) . DNA base excision repair (BER) is primarily responsible for repairing DNA damage generated by reactive oxygen species (ROS), environmental toxicants and cancer chemotherapeutic reagents (Fishel and Kelley, 2007) . In BER, apurinic/apyrimidinic endonucleases (APEs) generate 3 0 -OH termini at AP sites, abnormal bases and DNA single-strand breaks (Ischenko and Saparbaev, 2002; Izumi et al., 2003) . Escherichia coli and yeast cells defective in APE genes are inviable (Saporito et al., 1989; Guillet and Boiteux, 2002) . In mammals, deficiency of APE1 alone causes the embryonic lethality and apoptotic cell death in cultured cells (Xanthoudakis et al., 1996; Ludwig et al., 1998; Meira et al., 2001; Fung and Demple, 2005; Izumi et al., 2005) , clearly indicating that APEs are fundamental for cellular growth.
Post-translational modifications are important in modulating BER process. APE1 phosphorylation was first reported and shown to affect the repair and Ref-1 activities (Yacoub et al., 1997; Fritz and Kaina, 1999) . Bhakat et al. (2003) reported that acetylation specifically occurred on two Lys residues near the N-terminus of APE1 (K6 and K7). The acetylation enhanced APE1 binding to nCaRE (negative calcium response elements) consensus elements in DNA . The nCaRE binding by APE1 may have a significant impact on global gene expression as many other genes have been shown to contain nCaRE elements in their promoter regions (Okazaki et al., 1994; McHaffie and Ralston, 1995; Izumi et al., 1996; Fuchs et al., 2003) . Acetylation of APE1 was also found to activate the PTEN gene by a different mechanism from the nCaREoriented regulation (Fantini et al., 2008) . Therefore, a post-translational modification at N terminus of APE1 can affect its DNA-binding affinity and influence a variety of cellular metabolic functions.
Studies also have shown a correlation between a high level of APE1 and tumor resistance against chemotherapeutic drugs and ionizing radiation, implying that APE1 enhances repair and survival of these tumor cells (Koukourakis et al., 2001; Bao et al., 2006) . Subcellular distribution of APE1 has also been linked to tumor aggressiveness (Tell et al., 2005; Di Maso et al., 2007) . Colorectal adenoma and carcinoma cells showed higher concentrations of cytoplasmic APE1 than normal cells (Kakolyris et al., 1997) . Therefore, understanding the mechanism of subcellular localization of APE1 may provide new strategies for the cancer therapy (Tell et al., 2008) , as other studies have used DNA repair proteins as the target for the cancer therapy (Balusu et al., 2007; Jaiswal and Narayan, 2008) . Meira et al. (1997) reported that APE1 heterozygosity increased skin cancer onset when the XPC (xeroderma pigmentosum complementation group C) gene was nullizygous. This additive effect of APE1 on the cancer predisposition was nullified by inactivating p53, suggesting that APE1 was involved in tumor suppression regulated by p53 (Meira et al., 1997) . Consistently, BER enhancement by p53 was also reported (Zhou et al., 2001 ). Yet the regulatory function of p53 for the APE1 functions has not been established.
In this study, we report that APE1 was modified by ubiquitination that was increased following treatments with genotoxicants. We show that the modification was enhanced by mouse double minute 2 (MDM2) and was dependent on p53. We also identified the ubiquitin acceptor Lys residues at near N-terminus, namely, 24, 25, and 27K. To our knowledge, this is the first report for APE1 ubiquitination, and provides further evidence of the biological interaction between the BER and p53 signaling pathways.
Results
Decrease of APE1 during apoptosis has been reported in human cytolytic T cells and myelolytic cells (Robertson et al., 1997; Fan et al., 2003) . We examined the stability of APE1 after DNA damage generation by hydrogen peroxide (H 2 O 2 ) using Kasumi-1, a human myeloblastic leukemia cell line (Asou et al., 1991) . High molecular weight band (HWB) APE1 was detected in an immunoblot assay using an anti-APE1 antibody (top, Figure 1a ), whereas the amount of the intact APE1 was observed to decrease (bottom, Figure 1a ) by about 10% compared to the control, which is consistent with the small ratio of HWB relative to intact APE1. This result implies that APE1 was ubiquitinated.
To test the possibility of APE1 ubiquitination, we expressed APE1 and the His-tagged ubiquitin (His-ubi), a ubiquitin gene N-terminally tagged with the histidine hexamer, in the human colon carcinoma cell line HCT116. When the ubiquitinated proteins were purified and analysed with an anti-APE1 antibody, distinct APE1 bands appeared at a higher position than the intact APE1 in the SDS-polyacrylamide gel electrophoresis (lane 5, Figure 1b ). The generation of the HWB APE1 was dependent on the expression of the His-ubi (lane 5 vs lane 4), and the band position was consistent with that of a ubiquitin-APE1 fusion protein (lane 3). Next, we carried out an in vitro ubiquitination reaction using S100 fraction from HeLa cells supplemented with recombinant APE1 and ubiquitin proteins ( Figure 1c ). An HWB identical in size to the ubiquitinated APE1 of the previous experiments was detected only when the cell-free extract, APE1, and ubiquitin were all present in the reaction (lane 2).
Ubiquitin-like modifiers, that is, SUMO, Nedd8 and ISG15, have been demonstrated to modulate cellular factors including DNA repair proteins (Kerscher et al., 2006) . Because of their biochemical and functional similarities to ubiquitin, we tested the possibility of APE1 SUMOylation, Neddylation and ISGylation, using His-tagged SUMO, Nedd8 and ISG15 in the cells with the same assay as for ubiquitin. Under these conditions, we did not detect any modification of APE1 by the ubiquitin-like modifiers (data not shown).
On stress, p53 activates a number of genes that result in apoptosis, cell-cycle arrest or senescence (Shmueli and Oren, 2004) . On the basis of the genetic link between p53 and APE1 (Meira et al., 1997) , we examined the effects of DNA-damaging reagents, such as etoposide (a topoisomerase II inhibitor) and H 2 O 2 , on APE1 ubiquitination, because these reagents affect the intracellular p53 level. When HCT116 (p53 þ / þ or p53 À/À ) cells expressing the His-ubi and APE1 were treated with H 2 O 2 and etoposide, APE1 ubiquitination was significantly increased in the p53 þ / þ but not in the p53 À/À cells (Figure 2a ). These findings suggest that APE1 ubiquitination is dependent on the level of p53 and induced in response to cellular stress.
Although multiple ubiquitin E3 ligases for p53 are known, MDM2 is by far the most crucial regulator for p53 (Brooks and Gu, 2006) . Importantly, p53 activates MDM2 transcription due to a genotoxic stress, leading to a temporal increase of MDM2 (Iwakuma and Lozano, 2003) . For this reason, we tested whether MDM2 could catalyse the ubiquitination reaction on APE1. MDM2 was expressed along with the APE1 and His-ubi, and its effect on APE1 ubiquitination was examined. The amount of ubiquitinated APE1 was markedly increased by expressing MDM2, suggesting that MDM2 enhanced APE1 ubiquitination (Figure 2b ).
To determine whether the RING-finger domain of MDM2, critical for its E3 ubiquitin ligase activity, is required for the enhanced APE1 ubiquitination, a C464A MDM2 mutant lacking the proper RING conformation (Uldrijan et al., 2007) was used. The C464A MDM2 did not show any activity for APE1 ubiquitination (Figure 3a) , indicating that the RING domain was directly involved in this process. As an E3 ligase, MDM2 requires E1 (Uba1) and E2 ubiquitin ligases (Honda et al., 1997) . The in vitro ubiquitination reaction was carried out with recombinant APE1, ubiquitin, Ube1 (E1), UbcH5 (E2) and MDM2 RING domain ( Figure 3b ). Using only these components, we detected the ubiquitinated APE1, indicating that no other factors were essential for APE1 ubiquitination.
To further probe the mechanism for APE1 ubiquitination, the possibility of the direct interaction of APE1 with MDM2 was examined. Interaction between cellular APE1 and C464A MDM2 was detected by FLAG coimmunoprecipitation assay using FLAG-tagged APE1 (lane 1, Figure 3c ), whereas APE1 without FLAG epitope did not co-precipitate the C464A MDM2 protein (lane 3). Deleting APE1's N-terminal 41 amino-acid (aa) residues (ND42) caused no detectable effect on the MDM2 co-immunoprecipitation (lane 2), suggesting that the N-terminal region was not required for the interaction. Interestingly, the C-terminal 20 aa deletion of APE1 (CD20) repeatedly resulted in much more efficient co-precipitation of MDM2 than the fulllength APE1. It is likely that the C-terminal deletion exposed the presumptive interaction domain of APE1. Essentially the same results were obtained with the wildtype (wt) MDM2 and APE1 ( Supplementary Figure 1) .
The results indicate that the MDM2 RING structure is not essential for the interaction, and supports the idea that the MDM2 E3 ligase activity is directly involved in APE1 ubiquitination ( Figure 3a ).
Ubiquitination occurs only at e-amino groups of Lys residues, except for N-terminal ubiquitination (Bartel et al., 1990) . APE1 contains 29 Lys residues in its 318aa-long polypeptide, most of which are likely present on the APE1 surface and accessible by the ubiquitin ligase components. To determine whether the ubiquitination occurs at specific Lys residues of APE1, we examined its deletion mutants in the ubiquitin assay (lanes 2 and 3, Figure 4 ). Although ubiquitination of ND21 APE1 (20 aa N-terminal deletion) was comparable to that of the full-length APE1 (lane 2), ubiquitination of the ND42 APE1 (42 aa N-terminal deletion) was not detected (lane 3), indicating that the ubiquitination occurred inside of 21-42 from the APE1 N terminus. Because there were still six Lys residues in the segment (that is, 24, 25, 27, 31, 32 and 35K), we mutated each individually to Arg in the ND21 background. The triple K-to-R mutant K(31/ 32/35)R was effectively ubiquitinated (lane 5 vs 4, Figure 4 ), whereas the triple mutant K(24/25/27)R was ubiquitinated significantly less (lanes 7 and 8 vs 6, Figure 4 ). However, none of the single point mutations (that is, K24R, K25R or K27R) decreased the ubiquitination level (lanes 10-12, Figure 4 ). K(24/25/27)R mutations were introduced in the full-length APE1 and consistently reduced ubiquitination ( Figure 4 , lane 15 vs 13). We also examined three possible dual mutations, K(24/25)R, K(24/27)R and K(25/27)R, with the ubiquitination assay. The K24/25R mutant showed reduced ubiquitination (lane 14, Figure 4 ), whereas the other dual mutants exhibited the same level of ubiquitination as the wtAPE1 (data not shown). These results indicated that ubiquitination occurred preferentially to K24 and K25 rather than to K27. However, the fact that all the dual mutations failed to decrease APE1's ubiquitination to the level of the triple mutant (lane 15, Figure 4 ) suggests that these three Lys residues serve as backup ubiquitin acceptors when one is mutated. The ubiquitin acceptor Lys residues are in the 6 kDa stretch that is conserved among mammalian APEs. A ClustalW analysis revealed that the K24/K25/K27 residues are completely conserved among mammals (Supplementary Figure S2 ). Therefore, we predict that ubiquitination reactions at these sites occur to all mammalian APE1s. We also confirmed that both mouse Mdm2 and human MDM2 were efficient at enhancing APE1 ubiquitination (lanes 2 and 3, Figure 5a ). In Figure 5a , although polyubiquitinated APE1 was clearly detected (lanes 2 and 3), monoubiquitinated APE1 appeared to be stably formed throughout our ubiquitination assays. We inferred that monoubiquitinated APE1 might exist stably and that the modification would alter APE1 localization, as monoubiquitination does to p53 (Li et al., 2003) . The ubiquitin gene was thus inserted (sandwiched) in frame between the 23A and 24K residues of APE1, and was transfected into the mouse NIH3T3 cell line. The wtAPE1 was predominantly nuclear (i, Figure 5b ) as reported (Takao et al., 1998; Jackson et al., 2005) , whereas the ubiquitin-APE1 fusion protein was clearly excluded from the nuclei (ii, Figure 5b ). MDM2 is transcriptionally activated by p53. In turn, the accumulated MDM2 degrades p53 through polyubiquitination, forming a negative feedback loop (Vousden and Lane, 2007) . Nutlin, a potent inhibitor of MDM2 for p53 ubiquitination, specifically interferes with the interaction of MDM2 with p53 (Vassilev et al., 2004 ). An interesting possibility was that nutlin might also inhibit APE1 ubiquitination. If indeed this were the case, the nutlin-binding domain of MDM2 would be required for APE1 ubiquitination. APE1 might thus compete with p53 for MDM2 interaction. However, when HCT116 cells (p53 þ / þ ) were treated with nutlin-3, APE1 ubiquitination was significantly increased (Figure 6a ). Therefore, nutlin-3 did not interfere with APE1 ubiquitination through MDM2. The higher ubiquitination activity in the presence of nutlin-3 can be explained by the fact that nutlin-3 causes p53 stabilization, which increases the MDM2 level by transcriptional activation (Figure 6a ). Consistently, cells deficient in p53 (HCT116 p53 À/À ) did not respond to nutlin-3 by increasing APE1 ubiquitination (Figure 6a ). To detect ubiquitination on endogenous APE1, we transiently introduced the His-ubi alone to HCT116, which was then treated with nutlin-3. We observed the ubiquitinated form of endogenous APE1 (Figure 6b ), indicating that ubiquitination of endogenous APE1 can also occur depending on the intracellular level of MDM2.
To further probe the significance of MDM2 on APE1 stability, human MDM2-specific siRNA was introduced with the APE1 and His-ubi genes into the HCT116 cells ( Figure 6c ). The level of APE1 was significantly increased by MDM2 downmodulation, compared to that of cells treated with the control siRNA (Figure 6c ). Under the same condition, the cells that were also treated with nutlin-3 showed decreased APE1 levels (lane 2 vs 1 or 4 vs 3, Figure 6c ). Next, HCT116 cells (p53 þ / þ and p53 À/À ) were treated with nutlin-3 for 6 h. About 50% decrease in endogenous APE1 level was reproducibly observed in p53 þ / þ HCT116 cells, but not in the p53 À/À cells (Figure 6d ). Taken together, these data indicate that the stability of APE1 was regulated by MDM2 and p53 activities.
Discussion
Multiple studies have confirmed that downregulation of APE1 leads to cell sensitization spontaneously and by DNA-damaging reagents (Ono et al., 1994; Walker et al., 1994; Fung and Demple, 2005; Izumi et al., 2005) , and understanding the mechanism for regulating the APE1 level may provide new strategies for cancer therapy (Tell et al., 2008) .
It has been reported that APE1 is downregulated by apoptotic stimuli in certain types of blood cells (Robertson et al., 1997; Fan et al., 2003) . Downregulation of APE1 should enhance the apoptosis process, because reducing the cellular level of APE1 very likely enhances the cell death process. We have obtained multiple sources of evidence to support the existence of a ubiquitination reaction on APE1. First, the acute myeloblastic leukemia cell line Kasumi-1 showed the APE1 ladder formation. Although the amount of HWB was lower than that of the intact APE1, the appearance of the multiple HWBs could not be attributed to the other types of post-translational modifications than ubiquitination. The extent of the ladder formation appears to be cell-type specific, because different cell lines, including HCT116, A549 and U2OS, did not show detectable ubiquitination formation on APE1 by the same procedure (data not shown). It is known that multiple factors affect the level of ubiquitination, including the intracellular concentration of ubiquitin ligases and the extent of 'ubiquitin trapping' by other small-molecule modifier, most notably by ISG15 that is overexpressed in many tumor cell lines (Desai et al., 2006) . Moreover, ubiquitination is reversible by a number of deubiquitinases (DUBs) that remove the ubiquitin moieties from the modified proteins. For example, HAUSP (USP7) is the main DUB for p53 and has a significant function in stabilizing p53 in cells (Cummins et al., 2004) . Understanding the factors that regulate APE1 ubiquitination will be significant for predicting APE1 levels. Further evidence of APE1 ubiquitination was obtained using His-ubi. We observed that MDM2 and its known E2 ligase, UbcH5b (Honda et al., 1997; Badciong and Haas, 2002; Saville et al., 2004) , could carry out the APE1 ubiquitination reaction. MDM2 appears pivotal for the reaction, considering that the RING-finger mutant C464A MDM2 did not ubiquitinate APE1. Furthermore, this finding implies the involvement of p53, and is underscored by the enhancement of APE1 ubiquitination induced by such stimuli as H 2 O 2 , etoposide and nutlin-3. Unlike the DNA-damaging reagents, nutlin-3 disrupts the p53-MDM2 interaction and thus stabilizes p53. The enhancement of APE1 ubiquitination by nutlin-3 also indicates that APE1 interacts with MDM2 through an interface not shared with p53. It should be noted that although the direct interaction was observed between the transiently expressed APE1 and MDM2, we have not been able to detect the interaction between endogenous APE1 and MDM2. This unexpected result may be due to a technical limitation in detecting endogenous MDM2, which is notoriously unstable in vivo. It is also possible that a conformational change of APE1, probably involving the surface near APE1's C terminus (Figure 3c) , is required to enhance the specific interaction.
The N-terminal 6 kDa region of APE1, which contains the ubiquitin acceptor sites (K24, 25 and 27), is highly conserved among mammalian APE1. Although the N-terminal 6 kDa segment is not essential for the endonucleolytic activity of APE1, the domain is known to be important for interaction with other cellular factors including X-ray cross complementing group 1 (XRCC1), another essential BER protein (Vidal et al., 2001) . In addition, acetylation occurs at APE1's Lys6 and 7 , thus it would be interesting to test whether ubiquitination affects the accessibility of p300 for the acetylation reaction, or vice versa.
In our ubiquitin assay, monoubiquitinated APE1 was predominant over polyubiquitinated APE1. Therefore, it is possible that, once formed, monoubiquitinated APE1 remains stable in the cells before being polyubiquitinated. However, it should be pointed out that polyubiquitinated APE1 was also detected forming a ladder (lanes 2 and 3, Figure 5a ). We have yet to find a parameter to control the ratio of mono-and polyubiquitination on APE1. A similar dual-ubiquitination mechanism has been described by the numerous studies of p53 ubiquitination by MDM2. A critical factor for determining the ratio of the mono/polyubiquitination of p53 appears to be the in situ concentration of MDM2 (Li et al., 2003) . A higher concentration of MDM2 would generate more polyubiquitinated p53 for its degradation. A lower amount would result in monoubiquitinated p53. The latter modification confers additional functions to p53, such as self-promoted exclusion from nuclei (Li et al., 2003) and disruption of mitochondrial membrane potential (Marchenko et al., 2007) . More studies are necessary to understand whether the same parameter would apply to APE1. Alternatively, a cofactor may be required to enhance APE1 polyubiquitination, as monoubiquitinated p53 requires p300 (as an 'E4 ligase') to become fully polyubiquitinated (Grossman et al., 2003) . MDM2 is also a target of downregulation by such cellular factors as 14-3-3s (Yang et al., , 2007 , which could indirectly regulate ubiquitination of APE1. Finally, involvement of other ubiquitin ligases has been reported for p53 polyubiquitination. Pirh2 and COP1 almost exclusively polyubiquitinate p53 for its degradation. The present study supports the dual function of MDM2 by invoking the mono-and polyubiquitination reactions on APE1, which result in either functional alteration or degradation of APE1. Apart from p53 ubiquitination, histone ubiquitination by MDM2 was reported (Minsky and Oren, 2004) . Monoubiquitinated histone H2A/B can stably exist and modulate gene expression. Formation of stable monoubiquitinated APE1 may have a significant effect on cellular response to DNA damage, repair and apoptosis. We have provided evidence that the monoubiquitination would result in nuclear exclusion of APE1. Whether the nuclear exclusion of APE1 is a mechanism to decrease BER activity in nuclei and enhance apoptosis, or to lead to a novel event such as the interaction of APE1 with Bcl-2 (Zhao et al., 2008) in mitochondria awaits more dedicated, future studies. Here, the identification of specific Lys residues for APE1 ubiquitination should help study the effect of the monoubiquitination on APE1. Understanding the pathway for APE1 ubiquitination should provide critical knowledge not only of its physiological function, but of the APE1 upregulation mechanism in tumor tissues (Koukourakis et al., 2001; Bao et al., 2006; Tell et al., 2008) . APE1 regulation by p53 and MDM2 is clearly a complex mechanism, and understanding the function of ubiquitin in this signaling network should reveal the significance of the APE1/p53/MDM2 interdependence in the development of tumor malignancy.
Materials and methods
Cell culture and cDNA All cell culture media and reagents were purchased from Invitrogen (CA USA). Tumor cell lines used in this study included human cell lines U2OS and HCT116 (p53 þ / þ and p53 À/À ; Yu et al., 2002; Bhakat et al., 2003) and mouse NIH 3T3 (gift from Dr S Boldogh; ATCC, CRL-1658). The cells were grown in Dulbecco's minimum essential medium (DMEM) with F12 modification supplemented with 10% fetal bovine serum (FBS) and 1% streptomycin/penicillin. Kasumi-1, a human myeloblastic leukemia cell line isolated by Asou et al. (1991) , was purchased from ATCC and grown in RPMI 1640 with 20% FBS and 1% L-glutamine. Transfection experiments were carried out using lipofectamine 2000 according to the manufacturer's instruction.
The human Mdm2 homologue (MDM2) was purchased from MGC image clone library (Invitrogen). The human MDM2 gene was then cloned into Invitrogen's pcDNA3.1 Zeo( þ ) at the BamHI and XhoI sites by PCR. APE1 cDNA was subcloned into the pcDNA3.1 by PCR cloning to generate missense mutations and the ubiquitin fusions. The human ubiquitin gene was cloned into the pcDNA3.1 with introduction of N-terminal histidine hexamer. The G76A mutation in the ubiquitin gene was introduced by PCR. The primers used in this study are listed in the Supplementary Table 1 . All the DNA sequences amplified by PCR were confirmed for their predicted sequences. Co-immunoprecipitation assay for APE1-FLAG using FLAG antibody HCT116 cells were transfected with APE1-FLAG and C464A mutant MDM2, and lysed after 24 h in the IP buffer containing 50 mM Tris (pH 7.5), 100 mM NaCl, 15 mM EDTA, 0.1% Triton X-100, 1 mM DTT, Proteinase Inhibitor Cocktail (Roche) and 1 mM PMSF. After centrifugation, the supernatant was incubated with anti-FLAG antibody immobilized on agarose resin (M2-agarose; Sigma) for 1 h at 4 1C. After supernatant was removed from the resin by centrifugation at 1000 r.p.m. for 30 s, the proteins remaining with the resin were analysed by immunoblot assays using the anti-MDM2 (N-20; Santa Cruz, Santa Cruz, CA, USA) and anti-APE1 (Izumi et al., 1996) antibodies.
His-ubiquitin assay
Co-transfection of DNA and MDM2 siRNA Final concentration of 80 nM of control (UAGCGACUAAAC ACAUCAAUU; Dharmacon, Lafayette, CO, USA) or MDM2-specific siRNA (Santa Cruz), along with 0.25 mg of APE1 (full-length and ND21) and the His-ubi (G76A), was mixed with lipofectamine (Invitrogen) and added on to the HCT116 cells in the absence of FBS. After 6 h, DMEM/F12 with 10% FBS was added, and cells were lysed for immunoblot detection after further incubation for 30 h.
In vitro ubiquitination reaction
Purified ubiquitin ligases, that is, E1, UbcH5b and RINGfinger domain of MDM2, were purchased from Biomol (Plymouth Meeting, PA, USA). HeLa S100 fraction was purchased from Boston Biochem. Ubiquitin was a gift from Dr A Haas (LSUHSC, New Orleans, LA, USA). The in vitro ubiquitination reaction was carried out essentially in the same way as previously published (Badciong and Haas, 2002) . For the reaction using the recombinant ubiquitin ligases, purified APE1 (200 ng) was incubated with APE1 (20 ng), ubiquitin (20 ng), uba1 (10 ng), UbcH5b (20 ng) and MDM2 RING domain (20 ng) in 50 mM Tris (pH 7.6), 10 mM MgCl2, 1 mM DTT, 2 mM ATP, 10 mM creatine phosphate and kinase. The reaction using the S100 fraction was carried out based on the manufacturer's protocol. The reactions were carried out at 37 1C for 1 h, and then analysed in immunoblot assay using anti-APE1 antibody as was done for above assays.
Cellular localization of ubiquitin-APE1 fusion protein
Plasmid DNA for the 'sandwiched' ubiquitin-APE1 fusion was generated by inserting the ubiquitin gene between APE1's 23A and 24K amino acids. The Gly residue at the ubiquitin C terminus was changed to Ala (G76A) that is resistant to cellular DUB activity. NIH3T3 cells were transfected with the above-described DNA, and fixed with 3.7% formaldehyde after 24 h. The cells were then permeabilized with 0.2% Triton X solution, and stained with anti-APE1 antibody and 46diamidino-2-phenyl indole (DAPI). The localization of the fusion proteins was observed using Nikon TE2000 microscope.
Other reagents
When necessary, cells were incubated with DUB inhibitors, such as, 0.1 mM N-ethylmaleimide (Sigma), 10 mM LDN-57444 and 10 mM 4,5,6,7-tetrachloroindan-1,3-dione (Calbiochem, San Diego, CA, USA).
Abbreviations AP, apurinic/apyrimidinic; APE1, AP endonuclease 1; BER, base excision repair; MDM2, mouse double minute 2; His-ubi, Â 6 histidine-tagged ubiquitin; H 2 O 2 , hydrogen peroxide; ROS, reactive oxygen species; wt, wild type; XPC, xeroderma pigmentosum complementation group C; XRCC1, X-ray cross complementing group 1.
